8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

________________

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 4, 2007

E-Z-EM, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

0-13003	11-1999504
(Commission File Number)	(IRS Employer Identification No.)

1111 Marcus Avenue, Lake Success, New York	11042
(Address of Principal Executive Offices)	(Zip Code)

(516) 333-8230

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

|_|     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_|     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_|     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_|     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.     Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements of
                      Certain Officers.

(d)     On May 4, 2007, the Board of Directors of E-Z-EM, Inc. (the “Company”) elected Adel Michael to the Company's Board of Directors, effective immediately. The committee or committees of the Board of Directors on which Mr. Michael will serve have not yet been determined. Mr. Michael will receive the Company's standard director compensation for non-employee directors, which is described in the Company's proxy statement filed with the Securities and Exchange Commission on September 21, 2006.

A copy of the press release announcing Mr. Michael's election is attached hereto as Exhibit 99.1.

Item 9.01     Financial Statements and Exhibits

(d)     Exhibits.

99.1     Press Release dated May 8, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 9, 2007	E-Z-EM, INC.
	(Registrant)
	By: /s/ Peter J. Graham
	Peter J. Graham
	Senior Vice President –
	Chief Legal Officer, Global Human     Resources and Secretary

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Press release dated May 8, 2007.

EX-99.1

Exhibit 99.1

Company Contacts:	Investor Relations Contacts:
E-Z-EM, Inc.	Lippert/Heilshorn & Associates, Inc.
Tom Johnson (tjohnson@ezem.com )	Kim Sutton Golodetz ( kgolodetz@lhai.com)
(800) 544-4624 x3317	(212) 838-3777
www.ezem.com	Bruce Voss (bvoss@lhai.com )
	(310) 691-7100

FOR IMMEDIATE RELEASE

ADEL MICHAEL JOINS E-Z-EM BOARD OF DIRECTORS

LAKE SUCCESS, N.Y., May 8, 2007—E-Z-EM, Inc., (AMEX: EZM) today announced that Adel Michael was elected to its Board of Directors on May 4, 2007.

Mr. Michael, 63, is an experienced senior executive with a broad background in all aspects of business development and management. Over a distinguished thirty-five year career, he has held leadership positions with global responsibilities in finance, manufacturing, legal and IT systems, and general management. He also has extensive expertise in strategic acquisitions and divestitures, budgeting and planning, financial analysis and controls, profit modeling, international business, treasury and taxes.

Mr. Michael recently served as the Vice Chairman of the Board and Chief Financial Officer of Mentor Corporation (NYSE: MNT), a leading supplier of Medical Aesthetics and Urology products for the global market. Prior to Mentor he was Senior Vice President and Chief Financial Officer of Getz Brothers and Co. Inc., San Francisco, CA. a subsidiary of the Marmon Group Chicago, Il. Marmon is a major international conglomerate of manufacturing and services worldwide with annual revenues of over $7 billion and employing 40,000 employees, where Michael also served as a Corporate Controller. Michael was the Controller of Amphenol Corporation, a subsidiary of Allied / Signal Corporation in Toronto, Canada and Chicago, IL.

Commenting on the announcement, Paul S. Echenberg, Chairman of E-Z-EM, Inc., said, “The election of Adel to our board is a reflection of our desire to add new perspective and expertise to our board. Adel brings to us a wealth of experience and knowledge in strategic business development, and we look forward to the benefits of his guidance.”

About E-Z-EM, Inc.

E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company is the developer of VoLumen^®, the next generation low density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. The Company also offers Empower^®—the only family of CT injectors on the market with patented EDA™ technology that can help detect contrast extravasation—and offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation system. The Company is also the exclusive world-wide manufacturer and marketer of RSDL for first-responder organizations and military services. RSDL is a patented, broad-spectrum liquid chemical warfare (CW) agent decontaminant, that neutralizes or removes chemical agents from skin on contact, leaving a non-toxic residue that can be rinsed off with water.

The statements made in this document contain certain forward-looking statements. Words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates” or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company’s control. Such risks and uncertainties include: to develop its products, continued market acceptance and sales of VoLumen^®, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended March 3, 2007 and its Annual Report on Form 10-K for the fiscal year ended June 3, 2006. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.

# # #